Peer-reviewed veterinary case report
PET scans detect lymphoma and skin mast cell tumors in dogs
By LeBlanc, Amy K et al.·Published in Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2009·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma or mast cell tumors underwent a special imaging test called 18FDG-PET to help diagnose and manage their conditions. This test was able to show where the cancer had spread, including lymph nodes, liver, and spleen, and it helped veterinarians track how well chemotherapy was working. In dogs with mast cell tumors, the imaging also found cancer spread to lymph nodes that were missed during regular exams. Overall, 18FDG-PET proved to be a useful tool for staging these types of cancer in dogs, helping to guide treatment decisions.
People also search for: dog lymphoma treatment · mast cell tumor in dogs · 18FDG-PET imaging for dogs
Abstract
Positron Emission Tomography (PET) using the glucose analog 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) is a common imaging modality for diagnosis and management of many human malignancies. We evaluated 18FDG-PET in dogs with either multicentric lymphoma (LSA) or cutaneous mast cell tumor (MCT). A prototype large field-of-view PET scanner was used to collect whole-body images in nine dogs with LSA or MCT. Both tumors were characterized by avidity for 18FDG. In dogs with LSA, 18FDG-PET correctly identified involvement of superficial and internal lymph nodes, liver, and spleen. Repeated PET scans after induction chemotherapy demonstrated resolution of abnormal 18FDG uptake within these sites. In dogs with MCT, 18FDG-PET correctly identified MCT metastasis to regional lymph nodes in all dogs in which this was suspected or confirmed with cytology or biopsy before the PET scan. In two dogs, additional sites of mast cell disease were identified with 18FDG-PET that were undetected on physical examination and/or regional lymph node cytology. 18FDG-PET holds promise as a whole-body staging method for canine LSA and MCT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19400472/